Phase III failure of UCB's Cimzia may dash hopes of EU Crohn's approval
This article was originally published in Scrip
UCB's anti-inflammatory Cimzia (certolizumab pegol) failed to differentiate from placebo in a Phase III trial in Crohn's disease, show top-line results. Although the drug is already approved for Crohn's in the US, Switzerland and Canada, the trial was designed to build the case for EU and Japanese approvals in this indication. It is approved in the EU, Japan and the US for rheumatoid arthritis (RA).